--- title: Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer nct_id: NCT04801186 overall_status: COMPLETED sponsor: AstraZeneca study_type: OBSERVATIONAL primary_condition: Metastatic Castration-resistant Prostates Cancer countries: Colombia, Egypt, India, Peru, Saudi Arabia, South Korea, Turkey (Türkiye), United Arab Emirates canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04801186.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04801186" ct_last_update_post_date: 2023-09-07 last_seen_at: "2026-05-12T07:04:37.085Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer **Official Title:** REMPRO Registry A Multi-country, Multi-centre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer **NCT ID:** [NCT04801186](https://clinicaltrials.gov/study/NCT04801186) ## Key Facts - **Status:** COMPLETED - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 1920 - **Lead Sponsor:** AstraZeneca - **Conditions:** Metastatic Castration-resistant Prostates Cancer - **Start Date:** 2021-09-28 - **Completion Date:** 2022-09-30 - **CT.gov Last Update:** 2023-09-07 ## Brief Summary This is a multi-country, multi-centre, retrospective, non-interventional cohort study planned to include patients diagnosed with mCRPC between 01 January 2016 and 31 December 2018, who have received at least 1 line of treatment (LOT) in the mCRPC setting, and have 12 months of follow-up data available. ## Detailed Description This is a multi-country, multi-centre, retrospective, non-interventional cohort study planned to include patients diagnosed with mCRPC between 01 January 2016 and 31 December 2018, who have received at least 1 line of treatment (LOT) in the mCRPC setting, and have 12 months of follow-up data available.To describe the real-world treatment patterns in patients with mCRPC The data will be collected retrospectively between the date of diagnosis of mCRPC (index date) and the end of follow-up, i.e., until death, the last medical record entry, or the date of data extraction, whichever is the earliest. The data on different types of treatment received by the patients, sociodemographic and clinico-pathological characteristics, and healthcare utilization will be extracted from the medical records of patients (alive or deceased) into a centrally designed electronic data capture system. For the exploratory end point on real-world treatment patterns in patients with mCSPC, data on different types of treatment received by the patients, sociodemographic and clinico-pathological characteristics will be retrospectively extracted from the medical records of patients (alive or deceased) into a centrally designed electronic data capture system. ## Eligibility - **Minimum age:** 18 Years - **Sex:** MALE - **Healthy Volunteers:** No ``` Inclusion Criteria: * Male patients ≥18 years of age OR legal age of being an adult in the country as per local regulations 2. Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations 3. Patients with a diagnosis of metastatic (stage IV) mCRPC, confirmed by either biopsy of a metastatic tumour site or by history of biopsy-proven localized disease and evidence of metastatic disease on imaging studies (which is clearly noted in hospital/clinical records) and progression on ADT alone between 01 January 2016 and 31 December 2018 4. Availability of medical records at the participating site reflecting at least one LOT received in the mCRPC setting and 12 months of follow-up from the index date (unless the patient died or was lost to follow-up within the first 12 months after diagnosis) Exclusion Criteria: -1. Patients with a concomitant cancer at the time of diagnosis of mCRPC or those who are treated with any anti-cancer therapy indicated for other cancers within 6 months of diagnosis of mCRPC, except for non-metastatic non-melanoma skin cancers or in situ or benign neoplasms. 2\. Patients unable to give an informed consent (unless a waiver is granted) ``` ## Primary Outcomes - **Describe the real-world treatment patterns in patients with mCRPC** _(time frame: 12 Months)_ — Proportion of patients receiving each treatment regimen for each LOT - **Describe the real-world treatment patterns in patients with mCRPC** _(time frame: 12 Months)_ — Dose and DoT for each regimen for each LOT, reason(s) for stopping treatment regimen in each LOT and drug-free period D ## Secondary Outcomes - **Demographic and clinico-pathological profile** _(time frame: 12 Months)_ - **Survival outcomes associated with different treatment regimens used for mCRPC** _(time frame: 12 Months)_ - **Assess the real-world effectiveness** _(time frame: 12 Months)_ - **BRCA1/2 and HRRm status** _(time frame: 12 Months)_ ## Locations (30) - Research Site, Valledupar, Colombia - Research Site, Alexandria, Egypt - Research Site, Cairo, Egypt - Research Site, Cairo, Egypt - Research Site, Cairo, Egypt - Research Site, Cairo, Egypt - Research Site, Luxor, Egypt - Research Site, Ahmedabad, Gujarat, India - Research Site, Faridabad, Haryana, India - Research Site, Srinagar, Jammu and Kashmir, India - Research Site, Bengaluru, Karnataka, India - Research Site, Mumbai, Maharashtra, India - Research Site, New Delhi, National Capital Territory of Delhi, India - Research Site, New Delhi, National Capital Territory of Delhi, India - Research Site, New Delhi, National Capital Territory of Delhi, India - Research Site, Bhubaneswar, Odisha, India - Research Site, Secundrabad, Telangana, India - Research Site, Howrah, West Bengal, India - Research Site, Lima, Peru - Research Site, Riyadh, Saudi Arabia - Research Site, Riyadh, Saudi Arabia - Research Site, Goyang-si, Gyeonggi-do, South Korea - Research Site, Seongnam-si, Gyeonggi-do, South Korea - Research Site, Gangnam-gu, Seoul, South Korea - Research Site, Jongno-gu, Seoul, South Korea - Research Site, Seocho-gu, Seoul, South Korea - Research Site, Seodaemun-gu, Seoul, South Korea - Research Site, Turkey, Turkey, Turkey (Türkiye) - Research Site, Alain, United Arab Emirates, United Arab Emirates - Research Site, Dubai, United Arab Emirates ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `locations.research site|secundrabad|telangana|india` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.research site|valledupar||colombia` — added _(2026-05-12)_ - `locations.research site|alexandria||egypt` — added _(2026-05-12)_ - `locations.research site|cairo||egypt` — added _(2026-05-12)_ - `locations.research site|luxor||egypt` — added _(2026-05-12)_ - `locations.research site|ahmedabad|gujarat|india` — added _(2026-05-12)_ - `locations.research site|faridabad|haryana|india` — added _(2026-05-12)_ - `locations.research site|srinagar|jammu and kashmir|india` — added _(2026-05-12)_ - `locations.research site|bengaluru|karnataka|india` — added _(2026-05-12)_ - `locations.research site|mumbai|maharashtra|india` — added _(2026-05-12)_ - `locations.research site|new delhi|national capital territory of delhi|india` — added _(2026-05-12)_ - `locations.research site|bhubaneswar|odisha|india` — added _(2026-05-12)_ - `locations.research site|howrah|west bengal|india` — added _(2026-05-12)_ - `locations.research site|lima||peru` — added _(2026-05-12)_ - `locations.research site|riyadh||saudi arabia` — added _(2026-05-12)_ - `locations.research site|goyang-si|gyeonggi-do|south korea` — added _(2026-05-12)_ - `locations.research site|seongnam-si|gyeonggi-do|south korea` — added _(2026-05-12)_ - `locations.research site|gangnam-gu|seoul|south korea` — added _(2026-05-12)_ - `locations.research site|jongno-gu|seoul|south korea` — added _(2026-05-12)_ - `locations.research site|seocho-gu|seoul|south korea` — added _(2026-05-12)_ - `locations.research site|seodaemun-gu|seoul|south korea` — added _(2026-05-12)_ - `locations.research site|turkey|turkey|turkey (türkiye)` — added _(2026-05-12)_ - `locations.research site|alain|united arab emirates|united arab emirates` — added _(2026-05-12)_ - `locations.research site|dubai||united arab emirates` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT04801186.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT04801186* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*